240 related articles for article (PubMed ID: 33465283)
21. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
[TBL] [Abstract][Full Text] [Related]
22. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
23. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 in Children: Clinical Approach and Management.
Sankar J; Dhochak N; Kabra SK; Lodha R
Indian J Pediatr; 2020 Jun; 87(6):433-442. PubMed ID: 32338347
[TBL] [Abstract][Full Text] [Related]
25. Hemoperfusion with CytoSorb as Adjuvant Therapy in Critically Ill Patients with SARS-CoV2 Pneumonia.
Rampino T; Gregorini M; Perotti L; Ferrari F; Pattonieri EF; Grignano MA; Valente M; Garrone A; Islam T; Libetta C; Sepe V; Albertini R; Bruno R; Belliato M
Blood Purif; 2021; 50(4-5):566-571. PubMed ID: 33181508
[TBL] [Abstract][Full Text] [Related]
26. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
Vernaz N; Agoritsas T; Calmy A; Gayet-Ageron A; Gold G; Perrier A; Picard F; Prendki V; Reny JL; Samer C; Stirnemann J; Vetter P; Zanella MC; Zekry D; Baggio S
Swiss Med Wkly; 2020 Dec; 150():w20446. PubMed ID: 33382449
[TBL] [Abstract][Full Text] [Related]
27. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
Young BE; Ong SWX; Kalimuddin S; Low JG; Tan SY; Loh J; Ng OT; Marimuthu K; Ang LW; Mak TM; Lau SK; Anderson DE; Chan KS; Tan TY; Ng TY; Cui L; Said Z; Kurupatham L; Chen MI; Chan M; Vasoo S; Wang LF; Tan BH; Lin RTP; Lee VJM; Leo YS; Lye DC;
JAMA; 2020 Apr; 323(15):1488-1494. PubMed ID: 32125362
[TBL] [Abstract][Full Text] [Related]
28. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Kalantari S; Fard SR; Maleki D; Taher MT; Yassin Z; Alimohamadi Y; Minaeian S
J Med Virol; 2021 Dec; 93(12):6557-6565. PubMed ID: 34255369
[TBL] [Abstract][Full Text] [Related]
29. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
30. Blockage of interleukin-1β with canakinumab in patients with Covid-19.
Landi L; Ravaglia C; Russo E; Cataleta P; Fusari M; Boschi A; Giannarelli D; Facondini F; Valentini I; Panzini I; Lazzari-Agli L; Bassi P; Marchionni E; Romagnoli R; De Giovanni R; Assirelli M; Baldazzi F; Pieraccini F; Rametta G; Rossi L; Santini L; Valenti I; Cappuzzo F
Sci Rep; 2020 Dec; 10(1):21775. PubMed ID: 33311551
[TBL] [Abstract][Full Text] [Related]
31. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
[TBL] [Abstract][Full Text] [Related]
32. Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis.
Mastroianni A; Greco S; Chidichimo L; Urso F; Greco F; Mauro MV; Vangeli V
Int J Immunopathol Pharmacol; 2021; 35():20587384211059675. PubMed ID: 34928722
[TBL] [Abstract][Full Text] [Related]
33. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
34. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123
[TBL] [Abstract][Full Text] [Related]
35. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
37. Treatment of SARS-CoV-2: How far have we reached?
Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
[TBL] [Abstract][Full Text] [Related]
38. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
39. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
40. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
